Clinical and Experimental Nephrology

, Volume 18, Issue 6, pp 855–864 | Cite as

Effect of a combined treatment with erythropoietin and melatonin on renal ischemia reperfusion injury in male rats

  • Nasser Ahmadiasl
  • Shokofeh BanaeiEmail author
  • Alireza Alihemati
  • Behzad Baradaran
  • Ehsan Azimian
Original Article



Renal ischemia reperfusion (IR) is an important cause of renal dysfunction. It contributes to the development of acute renal failure. Oxidative damage from reactive oxygen species is considered to be the principal component involved in the pathophysiological tissue alterations observed during IR. The purpose of this study was to evaluate the effect of a combined treatment with erythropoietin (EPO) plus melatonin (MEL), which are known anti-inflammatory and antioxidant agents, in IR-induced renal injury in rats.


Wistar Albino rats were unilaterally nephrectomized and subjected to 45 min of renal pedicle occlusion followed by 24 h of reperfusion. MEL (10 mg/kg, i.p) and EPO (5000 U/kg, i.p) were administered prior to ischemia. After 24 h of reperfusion, blood samples were collected for the determination of superoxide dismutase (SOD), glutathione peroxidase (GPx), plasma levels of total antioxidant capacity (TAC), and malondialdehyde (MDA) and serum urea level. Also, renal samples were taken for histological evaluation.


Ischemia reperfusion significantly increased urea, blood SOD, and GPx levels. Histological findings of the IR group indicated that there was increase in tubular and glomerular hyaline cast, thickening of Bowman capsule basement membrane, and renal impairment in the glomerular epithelium. Treatment with EPO and MEL significantly decreased blood SOD, GPx, and urea levels and increased TAC level. In the EPO + MEL group, while the histopathological changes were lower than those in EPO group, they were the same as MEL group.


EPO and MEL combination treatment exerted more nephroprotective effects than EPO treatment and nearly had protective effects similar to MEL treatment.


Ischemia reperfusion injury Antioxidants Melatonin Erythropoietin Kidney 



This study was financially supported by Drug Applied Research Center of Tabriz University of Medical Sciences.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Grace PA. Ischaemia-reperfusion injury. Br J Surg. 1994;81:637–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Ischemia-reperfusion injury. J Surg Res. 2002;105:248–58.PubMedCrossRefGoogle Scholar
  3. 3.
    Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS, Matas AJ. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: the multivariate analysis. Transplantation. 1995;59:962–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Masztalerz M, Wlodarczyk Z, Czuczejko J, Slupski M, Kedziora J. Superoxide anion as a marker of ischemia-reperfusion injury of the transplanted kidney. Transpl Proc. 2006;38:46–8.CrossRefGoogle Scholar
  5. 5.
    Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med. 2000;109:655–78.CrossRefGoogle Scholar
  6. 6.
    Das DK, Maulik N. Antioxidant effectiveness in ischemia reperfusion tissue injury. Methods Enzymol. 1994;233:601–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Ikeda K, Negishi H, Yamori Y. Antioxidant nutrients and hypoxia/ischemia brain injury in rodents. Toxicology. 2003;189:55–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Rakotovao A, Berthonneche C, Guiraud A, de Lorgeril M, Salen P, de Leiris J, Boucher F. Ethanol, wine, and experimental cardioprotection in ischemia/reperfusion: role of the prooxidant/antioxidant balance. Antioxid Redox Signal. 2004;6:431–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Glantzounis GK, Salacinski HJ, Yang W, Davidson BR, Seifalian AM. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl. 2005;11:1031–47.PubMedCrossRefGoogle Scholar
  10. 10.
    Kacmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G. Octreotide improves reperfusion-induced oxidative injury in acute abdominal hypertension in rats. J Gastrointest Surg. 2004;8:113–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Singh D, Chander V, Chopra K. Protective effect of catechin on ischemia-reperfusion-induced renal injury in rats. Pharmocal Rep. 2005;57:70–6.Google Scholar
  12. 12.
    Benjamin B, Ebert L, Bunn HF. Regulation of erythropoietin gene. Blood. 1999;94:1864–77.Google Scholar
  13. 13.
    Siren AL, Ehrenreich H. Erythropoietin: a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001;251:179–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res. 2004;1000:19–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Westenfelder C, Biddle DL, Baranowski RL. Human, rat and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Calo LA, Bertipaglia L, Pagnin E. Antioxidants, carnitine and erythropoietin. G Ital Nefrol. 2006;34:47–50.Google Scholar
  17. 17.
    Aluclu MU, Acar A, Guzel A, Bahceci S, Yaldiz M. Evaluation of erythropoietin effects on cerebral ischemia in rats. Neuro Endocrinol Lett. 2007;28:170–4.PubMedGoogle Scholar
  18. 18.
    Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006;48:2161–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, Thiemermann C, Mota-Filipe H. Recombinant human erythropoietin protects the liver from hepatic ischemia reperfusion injury in the rat. Transpl Int. 2006;19:919–26.PubMedCrossRefGoogle Scholar
  20. 20.
    Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C, Zheng X, Jing H. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg. 2006;29:902–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Plotnikov EY, Chupyrkina AA, Jankauskas SS, Pevzner IB, Silachev DN, Skulachev VP, Zorov DB. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta. 2011;1812:77–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, Barlow-Warden LR. Melatonin: a highly potent endogenous radical scavenger and electron donor new aspects of the oxidation chemistry of this indole accessed in vitro. Ann NY Acad Sci. 1994;17:419–29.Google Scholar
  23. 23.
    Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 2000;7:444–58.PubMedCrossRefGoogle Scholar
  24. 24.
    Reiter RJ, Tan DX, Pilar Terron M, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings egarding their production and their radical scavenging actions. Acta Biochim Pol. 2007;54:1–9.PubMedGoogle Scholar
  25. 25.
    Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J. 1993;1:57–60.Google Scholar
  26. 26.
    Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189–200.PubMedCrossRefGoogle Scholar
  27. 27.
    Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, Reiter RJ. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine(AMK), in macrophages. J Neuroimmunol. 2005;165:139–49.PubMedCrossRefGoogle Scholar
  28. 28.
    Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005;39:215–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Maldonado MD, Murillo-Cabezas F, Terron MP, Flores LJ, Tan DX, Manchester LC, Reiter RJ. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res. 2007;42:1–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann NY Acad Sci. 1998;854:410–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Kurcer Z, Oguz E, Ozbilge H, Baba F, Aksoy N, Celik H, Cakir H, Gezen MR. Melatonin protects from ischemia/reperfusion-induced renal injury in rats: this effect is not mediated by proinflammatory cytokines. J Pineal Res. 2007;43(2):172–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;1(1):3.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105:328–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–69.PubMedGoogle Scholar
  36. 36.
    Ey Sšzmen, Sšzmen B, Delen Y, Onat T. Catalase/superoxide dismutase (SOD) and catalase/paraoxanase (PON) ratio may implicate poor glycemic control. Arch Med Res. 2001;32:283–7.CrossRefGoogle Scholar
  37. 37.
    Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application for monitoring the antioxidant status in premature neonates. Clin Sci. 1993;84:407–12.PubMedGoogle Scholar
  38. 38.
    Kiris I, Kapan S, Kilbas A, Yilmaz N, Altuntaş I, Karahan N, Okutan H. The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. J Surg Res. 2008;149:206–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Carden DL, Granger DN. Pathophysiology of ischemia reperfusion injury. J Pathol. 2000;190:255–66.PubMedCrossRefGoogle Scholar
  40. 40.
    Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky MS. Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol. 2001;281:F948–57.PubMedGoogle Scholar
  41. 41.
    Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol. 2003;16:63–74.PubMedGoogle Scholar
  42. 42.
    Kevin LG, Novalija E, Stowe DF. Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. Anesth Analg. 2005;101:1275–87.PubMedCrossRefGoogle Scholar
  43. 43.
    McCord JM. The evaluation of free radicals and oxidative stress. Am J Med. 2000;108:652–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Hagiwara S, Koga H, Iwasaka H, Kudo K, Hasegawa A, Kusaka J, Yokoi I, Noguchi T. ETS-GS, a new antioxidant, ameliorates renal ischemia-reperfusion injury in a rodent model. J Surg Res. 2011;171:226–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Schoenberg MH, Beger HG. Reperfusion injury after intestinal ischemia. Crit Med Care. 1993;21:1376–86.CrossRefGoogle Scholar
  46. 46.
    Mun KC, Lee HG, Lee TH, Kim YH, Kwak CS, Kim SP, Chang EJ, Park SB, Kim HC. Effect of modified polyhemoglobin on the ischemia/reperfusion injury in kidney. Transpl Proc. 2003;35:99–100.CrossRefGoogle Scholar
  47. 47.
    Kiris I, Okutan H, Savas C, Yönden Z, Delibaş N. Deneysel aortic iskemi-reperfuzyon modelinde renal hasara gadolinium klorurun etkisi.Turkish. J Vasc Surg. 2005;14:13–8.Google Scholar
  48. 48.
    Chen CF, Hsueh CW, Tang TS, Wang D, Shen CY, Pei JS. Reperfusion liver injury induced superoxide dismutase and catalase expressions and the protective effects of N-acetyl cysteine. Transpl Proc. 2007;39:858–60.CrossRefGoogle Scholar
  49. 49.
    Gulmen S, Kiris I, Narin C, Ceylan BG, Mermi B, Sutcu R, Meteoglu I. Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res. 2009;157:e7–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Evans P, Halliwell B. Micronutrients: oxidant/antioxidant status. Br J Nutr. 2001;85:S67–74.PubMedCrossRefGoogle Scholar
  51. 51.
    Dimitrijevic ZM, Cvetkovic TP, Djordjevic VM, Pavlovic DD, Stefanovic NZ, Stojanovic IR, Paunovic GJ, Velickovic-Radovanovic RM. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients. Int J Med Sci. 2012;9(9):808–15.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Ates E, Yalcin AU, Yılmaz S, Koken T, Tokyol C. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg. 2005;75:1100–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Reiter RJ, Oh C-S, Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol Metab. 1996;7:22–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Paller MS. Pathophysiologic mechanisms of acute renal failure. In: Goldstein RS, editor. Mechanisms of injury in renal disease and toxicity. Michigan: Ann Arbor CRC Press; 1994. p. 3–13.Google Scholar
  55. 55.
    Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transpl. 2006;21:330–6.CrossRefGoogle Scholar
  56. 56.
    Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol. 2008;294(2):F336–44.PubMedCrossRefGoogle Scholar
  57. 57.
    Song Y, Chan CW, Brown GM, Pang SF, Silverman M. Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J. 1997;11(1):93–100.PubMedGoogle Scholar
  58. 58.
    Singh I, Gulati S, Orak JK, Singh AK. Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Mol Cell Biochem. 1993;125:97–104.PubMedCrossRefGoogle Scholar
  59. 59.
    Davies SJ, Reichardt-Pascal SY, Vaughan D, Russell GI. Differential effect of ischaemia-reperfusion injury on anti-oxidant enzyme activity in the rat kidney. Exp Nephrol. 1995;3:348–54.PubMedGoogle Scholar
  60. 60.
    Conti M, Eschwege P, Ahmed M, Paradis V, Droupy S, Loric S, Bedossa P, Charpentier B, Legrand A, Benoit G. Antioxidant enzymatic activities and renal warm ischemia: correlation with the duration of ischemia. Transpl Proc. 2000;32:2740–1.CrossRefGoogle Scholar
  61. 61.
    Li Z, Nickkholgh A, Yi X, Bruns H, Gross ML, Hoffmann K, Mohr E, Zorn M, Büchler MW, Schemmer P. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation. J Pineal Res. 2009;46:365–72.PubMedCrossRefGoogle Scholar
  62. 62.
    Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects he kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115–24.PubMedCrossRefGoogle Scholar
  63. 63.
    Vesey DA, Cheung C, Pat B, Endre Z, Gobé G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348–55.PubMedCrossRefGoogle Scholar
  64. 64.
    Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yegen BC. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res. 2002;32:120–6.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2014

Authors and Affiliations

  • Nasser Ahmadiasl
    • 1
  • Shokofeh Banaei
    • 2
    Email author
  • Alireza Alihemati
    • 3
  • Behzad Baradaran
    • 4
  • Ehsan Azimian
    • 5
  1. 1.Drug Applied Research CenterTabriz University of Medical SciencesTabrizIran
  2. 2.Department of PhysiologyTabriz University of Medical SciencesTabrizIran
  3. 3.Department of Histology and EmbryologyTabriz University of Medical SciencesTabrizIran
  4. 4.Department of ImmunologyTabriz University of Medical SciencesTabrizIran
  5. 5.Department of Linguistics and Foreign LanguagesPayame-Noor UniversityTehranIran

Personalised recommendations